ALNY Q2 2023 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$319M+41.8% YoY

Gross Profit

$233M73.2% margin

Operating Income

-$230M-72.1% margin

Net Income

-$276M-86.6% margin

EPS (Diluted)

$-2.21

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$75M

Stock-Based Comp.

$76M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$3.8B

Stockholders' Equity

-$408M

Cash & Equivalents

$658M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$319M	$225M	+41.8%
Gross Profit	$233M	$184M	+26.8%
Operating Income	-$230M	-$192M	-19.9%
Net Income	-$276M	-$277M	+0.5%

Revenue Segments

Product

$306M98%

Royalty

$7M2%

Geographic Segments

Europe

$12M50%

UNITED STATES

$9M36%

Non-US Or Europe

$3M13%